PlainPharmaWatch

CMS Open Payments · Tool

Saluda Medical Americas, Inc. vs AstraZeneca AB

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

AstraZeneca AB has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 9,332, versus 278 for the other company. Its single largest recorded recipient represents 96.6% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Saluda Medical Americas, Inc.
HHI 278 · top recipient 11.7%
Ranked #1,478 of 1,838 companies by HHI
AstraZeneca AB
HHI 9,332 · top recipient 96.6%
Ranked #162 of 1,838 companies by HHI

Payment Overview

Total Payments
$2.4M
% of Industry
0.0%
Transactions
11,687
Avg per Transaction
$208.98
Recipients
11,524
Avg per Recipient
$211.94
Payment Types
3
Top Payment Type
Consulting Fee
Company B

AstraZeneca AB

Total Payments
$2.5M
% of Industry
0.0%
Transactions
62
Avg per Transaction
$39.6K
Recipients
46
Avg per Recipient
$53.4K
Payment Types
4
Top Payment Type
Compensation for Services Other Than Consulting

Highlighted values indicate the higher figure for each metric.

Total payments compared

Saluda Medical Americas, Inc. vs AstraZeneca AB - total reported payments in CMS Open Payments PY2024

AstraZeneca AB$2.5MSaluda Medical Americas, In…$2.4M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Saluda Medical Americas, Inc.

Consulting Fee $1.1M

58.4%

Food and Beverage $499.6K

27.3%

Travel and Lodging $261.4K

14.3%

AstraZeneca AB

Compensation for Services Other Than Consulting $1.5M

96.6%

Consulting Fee $51.7K

3.3%

Food and Beverage $701.19

0.0%

Travel and Lodging $467.61

0.0%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Saluda Medical Americas, Inc.

  1. 1

    Jason Pope

    $214,415.28 · 133 txns

  2. 2

    Johnathan Goree

    $100,060.90 · 84 txns

  3. 3

    Erika Petersen

    $91,063.40 · 46 txns

  4. 4

    Nagy Mekhail

    $67,445.95 · 24 txns

  5. 5

    Ajay Antony

    $64,278.04 · 46 txns

AstraZeneca AB

  1. 1

    Univ Of Mi Hospitals & Hlth Ctrs

    $1,500,537.00 · 2 txns

  2. 2

    VANITA Ramprakash ARODA

    $7,974.46 · 3 txns

  3. 3

    Antonio Anzueto

    $7,023.96 · 1 txns

  4. 4

    Eric Smith Orwoll

    $6,510.00 · 1 txns

  5. 5

    GEOFFREY L CHUPP

    $5,772.75 · 3 txns

Summary Comparison

Metric Saluda Medical Americas, Inc. AstraZeneca AB
Total Payments $2.4M $2.5M
% of Industry Total 0.0% 0.0%
Transaction Count 11,687 62
Avg per Transaction $208.98 $39.6K
Recipient Count 11,524 46
Avg per Recipient $211.94 $53.4K
Payment Type Count 3 4
Top Payment Type Consulting Fee Compensation for Services Other Than Consulting

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.